FT895
目录号 : GC65206
FT895是组蛋白脱乙酰酶11(Histone Deacetylase 11,HDAC11)的有效选择性抑制剂,IC50值为3nM。
Cas No.:2225728-57-2
Sample solution is provided at 25 µL, 10mM.
FT895 is an effective selective inhibitor of histone deacetylase 11 (HDAC11), with an IC50 value of 3nM [1]. HDAC11 is a novel and unique member of the histone deacetylase family, which is highly expressed in specific tissues and certain cancer cell lines [2]. HDAC11 possesses both histone and non-histone[3] deacetylase activities and can participate in cellular activities such as chromatin remodeling and metabolic signaling pathways by regulating the acetylation state of the cell[3]. As a selective inhibitor of HDAC11, FT895 has demonstrated excellent cellular activity and pharmacokinetic properties[4], making FT895 an effective tool for studying the biological mechanisms of HDAC11. Additionally, FT895 holds promising applications in the treatment of cancer and inflammatory diseases.
In vitro, treatment with FT895 (10μM) for 24 hours resulted in a significant reduction of migration ability in A549 and H1650 cells[5]. Treatment with FT895 (10μM) for 1 hour resulted in a significant improvement of bactericidal efficiency in BMDM (Bone Marrow Derived Macrophage) cells[6].
In vivo, intraperitoneal injection of FT895 (10mg/kg/day) for 5 days in C57BL/6J mice promoted the expression of the mitochondrial inner membrane transporter UCP1 (Uncoupling protein 1) in adipose tissue through the inhibition of HDAC11, ultimately resulting in an increase in core body temperature in mice [7]. Intraperitoneal injection of FT895 (50mg/kg/day) for 7 days in C57BL/6 mice led to the inhibition of HDAC11 activity, which upregulated the expression of the anti-inflammatory cytokine IL-10 (Interleukin-10), thereby promoting anti-inflammatory responses and reducing the replication of enteric virus EV71 in the mice[8].
References:
[1] Huang, P.-Y., et al., FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. International Journal of Molecular Sciences, 2023. 25(1).
[2] Lin Gao, M.A.C., Fred Asselbergs, Peter Atadja, Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family. Journal of Biological Chemistry, 2002. 277(28): p. 25748-25755.
[3] Joshi, P., et al., The functional interactome landscape of the human histone deacetylase family. Molecular Systems Biology, 2013. 9(1): p. 672.
[4] Matthew W. Martin, J.Y.L., David R. Lancia, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Maureen S. Lynes, C. Gary Marshall, Chiara Conti, Alan Collis, Monica Alvarez Morales, Kshama Doshi, Aleksandra Rudnitskaya, Lili Yao, Xiaozhang Zheng, Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11. Bioorganic & Medicinal Chemistry Letters, 2018. 28(12): p. 2143-2147.
[5] Bora-Singhal, N.e.a., Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2. Scientific reports, 2020. 10,1 4722.
[6] Wu, H.e.a., HDAC11 negatively regulates antifungal immunity by inhibiting Nos2 expression via binding with transcriptional repressor STAT3. Redox biology, 2022. 56 (2022): 102461.
[7] Robinson EL, B.R., Major JL, Bergman BC, Matsuda JL, McKinsey TA, HDAC11 inhibition triggers bimodal thermogenic pathways to circumvent adipocyte catecholamine resistance. J Clin Invest, 2023.
[8] Xie, H.e.a., Targeting HDAC11 activity by FT895 restricts EV71 replication. Virus research, 2023. vol. 330 (2023): 199108.
FT895是组蛋白脱乙酰酶11(Histone Deacetylase 11,HDAC11)的有效选择性抑制剂,IC50值为3nM[1]。HDAC11 是组蛋白脱乙酰酶家族的一个新颖且独特的成员,在特定组织和某些癌细胞系中大量表达[2]。HDAC11具有组蛋白[2]和非组蛋白[3]脱乙酰酶活性,可以通过调节细胞的乙酰化状态,参与染色质重塑和代谢信号通路等细胞活动[3]。FT895作为HDAC11的选择性抑制剂,展现出了的良好的细胞活性和药代动力学特性[4],是研究 HDAC11 生物学机制的有效工具。
在体外,FT895(10μM)处理A549和H1650细胞24h,可显著降低A549和H1650细胞的细胞迁移能力[5]。FT895(10μM) 处理BMDM(Bone Marrow Derived Macrophage,骨髓来源巨噬细胞) 细胞1h,可显著提升BMDM细胞的杀菌效率[6]。
在体内,FT895(10mg/kg/day)腹腔注射处理C57BL/6J小鼠5天,FT895通过对HDAC11的抑制作用,促进了小鼠体内脂肪组织中线粒体内膜转运蛋白UCP1(Uncoupling protein 1)的表达,最终表现为小鼠核心体温升高[7]。FT895(50mg/kg/day)腹腔注射处理C57BL/6小鼠天7天,FT895通过抑制HDAC11的活性,上调了抗炎因子 IL-10 (Interleukin-10)的表达,促进了抗炎反应并减少了小鼠体内肠道病毒 EV71 的复制[8]。
Cell experiment [1]: | |
Cell lines |
A549,H1650 |
Preparation Method |
A549 and H1650 cells need to be cultured in 6-well plates until 90-95% confluent. Then a sterile 2µl pipette tip is used to create a scratch in each hole. Wash the cells with PBS, and then incubate the cells at 37°C for 24h in a medium supplemented with 10μM FT895. Finally, images of the wound healing process will be captured using a suitable imaging system for observation and analysis. |
Reaction Conditions |
10 μM;24h |
Applications |
Treatment with FT895 (10μM) for 24 hours resulted in a significant reduction of migration ability in A549 and H1650 cells. |
Animal experiment [2]: | |
Animal models |
C57BL/6J mice |
Preparation Method |
A suitable number of 6-week-old C57BL/6 male mice should be prepared and placed in clean, individually ventilated cages. Then mice will be infected with 1 × 106 PFU Gluc-EV71 in 100 µl PBS for 7 days. Simultaneously, FT895 (50mg/kg/day) will also be intraperitoneally injected for 7 days. Finally, the virus copy number can be determined by qPCR. |
Dosage form |
50mg/kg/day for 7 days; i.p. injection |
Applications |
FT895 (10mg/kg/day) upregulates the expression of the anti-inflammatory factor IL-10 (Interleukin-10) in C57BL/6J mice, promotes anti-inflammatory responses, and reduces the replication of the enterovirus EV71 in mice. |
References: |
Cas No. | 2225728-57-2 | SDF | Download SDF |
分子式 | C16H15F3N4O2 | 分子量 | 352.31 |
溶解度 | DMSO : 125 mg/mL (354.80 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.8384 mL | 14.192 mL | 28.3841 mL |
5 mM | 0.5677 mL | 2.8384 mL | 5.6768 mL |
10 mM | 0.2838 mL | 1.4192 mL | 2.8384 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet